Who
Michael Singer
Director
Company insider
Files Form 4 as: Director and 10% owner, Cartesian Therapeutics.
In numbers
- Trades disclosed
- 42
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 13 Nov 2023
- Last trade
- 13 Mar 2026
- Last filed
- 13 Mar 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Mar 2026filed 13 Mar 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code G | —6,555 at $0.00 | filing |
| 13 Mar 2026filed 13 Mar 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code G | —6,555 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,600 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,600 at $0.00 | filing |
| 18 Nov 2025filed 19 Nov 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code G | —20,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,600 at $0.00 | filing |
| 26 Dec 2024filed 30 Dec 2024 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code G | —20,000 at $0.00 | filing |
| 19 Nov 2024filed 21 Nov 2024 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code G | —28,821 at $0.00 | filing |
| 8 Apr 2024filed 10 Apr 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,304.56 | filing |
| 8 Apr 2024filed 10 Apr 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,316.26 | filing |
| 8 Apr 2024filed 10 Apr 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,672.39 | filing |
| 8 Apr 2024filed 10 Apr 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —210.15 | filing |
| 8 Apr 2024filed 10 Apr 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —436.07 | filing |
| 8 Apr 2024filed 10 Apr 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,837.05 | filing |
| 8 Apr 2024filed 10 Apr 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,837.05 | filing |
| 8 Apr 2024filed 10 Apr 2024 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code M | —110,151 | filing |
| 8 Apr 2024filed 10 Apr 2024 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code M | —377,208 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.